Navigation Links
WuXi PharmaTech Announces First-Quarter 2010 Results
Date:5/11/2010

nciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to favorable industry trends, guidance for second-quarter and full-year 2010 performance, anticipated strong financial results for 2010 and beyond, and anticipated benefits of the proposed combination with Charles River Laboratories, are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Risks with respect to the proposed combination include: (i) the companies may be unable to obtain stockholder or regulatory approvals required for the combination; (ii) problems may arise in successfully integrating the businesses of the two companies; (iii) the acquisition may involve unexpected costs; (iv) the combined company may not achieve the anticipated transaction benefits; (v) restrictions in our acquisition agreement with Charles River that require us to conduct our business in the ordinary course consistent with past practices and in accordance with other specific limitations may delay or prevent us from taking advantage of business opportunities that may arise prior to the combination; and (vi) the businesses may suffer as a result of uncertainty surrounding the combination. In addition, the businesses ma
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
2. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
3. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
6. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
7. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. Jazz Pharmaceuticals Announces Public Offering of Common Stock
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
11. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... -- Cepheid (NASDAQ: CPHD) announced today the release of ... test for rapid, accurate and reliable determination of ... infection. The test will be marketed as a ... In Vitro Diagnostic Medical Devices, bringing the ... XC runs on Cepheid,s GeneXpert ® System, ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... Researchers in New Delhi, India have published a ... exposed to asbestos-contaminated work clothes for just 3 months as ... report in a new article. Click here to read ... say their patient was diagnosed with mesothelioma after ... she had come in contact with her miner father’s dirty ...
(Date:9/2/2014)... Headaches, both chronic and acute ruin lives. ... family and friends, sleeping and just coping well with daily ... of disability worldwide. The medications prescribed for these conditions ... of these cases of headache and back pain are of ... will not detect and fix the cause. , When ...
(Date:9/2/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... Hospital in Sioux Falls, S.D. The top executive ... has recently placed more than 900 healthcare executives into ... physician-owned healthcare provider and nationally recognized leader in patient-centered ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Physical Therapists in Houston Learn Pain Relief Techniques 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3
... from the Journal of Traumatic Stress finds ... who are happily married, communicating frequently with one,s spouse ... the development of posttraumatic stress disorder (PTSD) symptoms after ... male Army soldiers who returned from military deployment within ...
... (BUSM) researchers have found that Gabapentin, (trade name Neurontin) ... and biopolar disease in older and elderly patients, seems ... to experience orgasm, than previously reported. This study ... Journal of Geriatric Pharmacotherapy . Anticonvulsants are the ...
... , THURSDAY, June 2 (HealthDay News) -- People ... hospitalization are more than twice as likely to be readmitted ... a new study has found. The finding suggests that ... patients, according to the researchers, who were to present the ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating ... site infections, new study findings suggest. In the ... Journal of Surgery , the Swiss researchers also said these ... costly hospital stays. "SSIs lead to patients spending up ...
... an investigational vaccine made from their own frozen immune ... with it, according to data being presented by researchers ... 2011 American Society of Clinical Oncology annual meeting in ... In an exploratory, multi-institutional analysis, researchers administered the ...
... By Kathleen Doheny HealthDay Reporter , ... that low-carbohydrate diets, with regular exercise as part of ... some experts have feared. "It,s pretty clear low-carb ... J. Stewart, director of clinical and research exercise physiology ...
Cached Medicine News:Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: